Business
The INM-089 and INM-901 preclinical programs offer a differentiated treatment approach using proprietary, disease-modifying small molecules that target the CB1 and CB2 receptors, which management believes is a key strength of the Company.
InMed Pharmaceuticals Inc.: Revenue grew 7.5% to $4.943M from $4.598M. Net loss widened to $8.162M from $7.676M. Free cash flow outflow widened to $7.776M from $6.995M. Net margin expanded 180 bps to -165.14%. InMed Pharmaceuticals Inc.'s annual comparison also shows free cash flow declined despite revenue growth; margins improved while free cash flow declined.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 7.5% to $4.943M from $4.598MOK
- Profitability — Net loss widened to $8.162M from $7.676MWatch
- Cash flow — Free cash flow outflow widened to $7.776M from $6.995MWatch
- Margins — Net margin expanded 180 bps to -165.14%OK
- Accounting — No overriding statistical warningNote
- Insiders — 0 purchases and 0 salesNote
Where the revenue comes from
Fiscal 2025, as InMed Pharmaceuticals Inc. reports it. History and quarterly detail are in the app.
- Reportable Subsegments$4.9M
Leadership changes
From InMed Pharmaceuticals Inc.'s own filings, the day they're filed.
- John Bathery · director · appointmenteff. 2025-10-14
- Neil Klompas · director · appointmenteff. 2025-10-09
- N. Netta · Chief Financial Officer · appointmenteff. 2024-02-20
Latest filings
- 8-K · Company announcement2026-06-10
- 8-K · Company announcement2026-05-19
- 8-K · Company announcement2026-05-19
- 8-K · Company announcement2026-05-07
- 10-Q · Quarterly report2026-05-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about InMed Pharmaceuticals Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.